Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females who are 10 - 17 years of age~* History of type 2 diabetes~* Nonsmoker~* No clinical or laboratory evidence to indicate a diagnosis of type 1 diabetes~Exclusion Criteria:~* History of diabetic ketoacidosis~* History of stroke, chronic seizures or major neurological disorder~* Consumes alcohol~* Consume more than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola or other beverages containing caffeine per day~* Unable to swallow tablets~* Has had surgery, donated or lost 1 unit of blood, or participated in another investigational study within a minimum of 4 weeks prior to starting the study~* History of multiple and/or severe allergies or has had an allergic reaction to or significant intolerability to prescription or non-prescription drugs or food~* Currently a regular user of any illicit drugs or has a history of drug or alcohol abuse~* History of clinically significant endocrine, gastrointestinal,~cardiovascular, hematological, hepatic, immunological, renal, respiratory, or~genitourinary abnormalities or diseases~* Has an estimated creatinine clearance of less than or equal to 80 mL/min

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin 50 mg (Type: EXPERIMENTAL): Participants were randomized to sitagliptin 50 mg
- Sitagliptin 100 mg (Type: EXPERIMENTAL): Participants were randomized to sitagliptin 100 mg
- Sitagliptin 200 mg (Type: EXPERIMENTAL): Participants were randomized to a single dose of sitagliptin 200 mg
- Placebo to sitagliptin (Type: PLACEBO_COMPARATOR): Participants were randomized to matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).